BioSpace News Archive

AffyImmune Therapeutics today announced that Matt Britz, President, will participate in a virtual fireside chat at the Evercore ISI 2024 Emerging Biotech Conference on February 29, 2024.

Natera, Inc. today announced that it will release results for its fourth quarter and year ended December 31, 2023, after the market close on Feb. 28, 2024.

Koneksa announced today that the first patient was enrolled in the LEARNS study, an observational study to determine the measurement reliability and responsiveness over time of digital biomarkers, using mobile and wearable-based assessments to improve signal detection for potential disease modifying therapies in neurodegenerative conditions including Parkinson’s disease.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an agreement with Pluristyx Inc., a leading provider of tools, technologies, and services for the development of cell therapies.

Immunome, Inc. today recognized the announcement by Ayala Pharmaceuticals, Inc. that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors.

Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, is pleased to share the publication of promising early clinical data with 177Lu-rhPSMA-10.1 from independent clinical experience by physicians at the University Hospital Augsburg, Germany.

enVVeno Medical Corporation today announced that topline efficacy data from the VenoValve U.S. pivotal trial will be presented at the 2024 American Venous Forum (AVF) Annual Meeting being held March 3-6, 2024 in Tampa, Florida.

Cannabis Bioscience International Holdings, a Houston-based company trading on the OTC Markets under the ticker symbol CBIH, has engaged the services of Bull in Advantage as its Investor Relations firm.

Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”) today announced publication in Anesthesiology Journal of results from an investigator-initiated research study using ZTlido® for the treatment of chronic neck pain.

Gemini BioProducts Holding, Inc. announced the appointment of Mike Guerra to its Board of Directors.